Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdermabrasion plus topical bimatoprost versus topical bimatoprost alone for vitiligo
IRCT20220129053866N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of bimatoprost in Vitiligo (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoint: Repigmentation percentage. Started Mar 2022; status: completed.
02
Drugs
bimatoprost
03
Conditions
Vitiligo
Beyond the preview
Go deeper on IRCT20220129053866N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220129053866N1.